TIOTROPIUM (Spiriva HandiHaler® or Spiriva Respimat®)

Clinical Indication

COPD

Comments

The LLR COPD guidelines have been updated (June 2026) and LAMAs are no longer routinely recommended as a treatment option. No NEW initiations. For patients established on this therapy, treatment should be reviewed on a case-by-case basis, taking into account clinical stability and patient preference. Ongoing prescribing should be in line with the updated COPD guidelines.

Date of classification

November 2016

Green

Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.